TNF-α G-308A polymorphism has been shown to influence clinical outcomes in sarcoidosis patients treated with infliximab and adalimumab [50].In this review, we reported six studies on the anti-TNF-α intervention that resulted in partial to complete resolution of CS lesions after several months. This evidence concerns the gene TNF and Cowden syndrome 1.